Existing and Future Drugs for the Treatment of the Dark Side of Addiction

Annual Review of Pharmacology and Toxicology

Volumn 56, Issue , 2016, Pages 299-322

  Koob, George F ^a   Mason, Barbara J ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Alcoholism; Drug addiction; Medication development; Neurobiology; Relapse; Stress; Withdrawal

Indexed keywords

ACAMPROSATE; AMFEBUTAMONE; BUPRENORPHINE; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DYNORPHIN DERIVATIVE; ENDOCANNABINOID; GLUTAMIC ACID DERIVATIVE; KAPPA OPIATE RECEPTOR ANTAGONIST; METHADONE; NALTREXONE; NEUROPEPTIDE Y; NICOTINE GUM; NICOTINE LOZENGE; NICOTINE PATCH; NOCICEPTIN; PARTIAL AGONIST; VARENICLINE; DRUG;

ADDICTION; ALCOHOLISM; ANIMAL MODEL; ARTICLE; CLINICAL TRIAL (TOPIC); DRUG DEPENDENCE; DRUG RESEARCH; DRUG TARGETING; HUMAN; NEUROBIOLOGY; NEUROTRANSMISSION; NONHUMAN; OPIATE ADDICTION; PRIORITY JOURNAL; STRESS; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME; ANIMAL; BEHAVIOR, ADDICTIVE; DRUG DEVELOPMENT; PROCEDURES; SUBSTANCE-RELATED DISORDERS;

ANIMALS; BEHAVIOR, ADDICTIVE; DRUG DISCOVERY; HUMANS; PHARMACEUTICAL PREPARATIONS; SUBSTANCE-RELATED DISORDERS;

EID: 84954186413     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-010715-103143     Document Type: Article

References (148)

1. Koob GF, Le Moal M. 2008. Addiction and the brain antireward system. Annu. Rev. Psychol. 59:29-53
2. Piazza PV, Deroche V, Deminiere JM, Maccari S, Le Moal M, Simon H. 1993. Corticosterone in the range of stress-induced levels possesses reinforcing properties: implications for sensation-seeking behaviors. PNAS 90:11738-42
3. Koob GF, Lloyd GK,Mason BJ. 2009. Development of pharmacotherapies for drug addiction: A Rosetta Stone approach. Nat. Rev. Drug Discov. 8:500-15
4. Volkow ND, Wang GJ, Telang F, Fowler JS, Logan J, et al. 2007. Profound decreases in dopamine release in striatum in detoxified alcoholics: possible orbitofrontal involvement. J. Neurosci. 27:12700-6
5. Mitchell JM,O'Neil JP, Janabi M, Marks SM, Jagust WJ, FieldsHL. 2012. Alcohol consumption induces endogenous opioid release in the human orbitofrontal cortex and nucleus accumbens. Sci. Trans. Med. 4:116ra6
6. Heimer L, Alheid G. 1991. Piecing together the puzzle of basal forebrain anatomy. In The Basal Forebrain: Anatomy to Function, ed. TC Napier, PWKalivas, I Hanin, pp. 1-42. New York: Plenum
7. CarlezonWA Jr, Nestler EJ, Neve RL. 2000. Herpes simplex virus-mediated gene transfer as a tool for neuropsychiatric research. Crit. Rev. Neurobiol. 14:47-67
8. Jonas DE, Amick HR, Feltner C, Bobashev G, Thomas K, et al. 2014. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: A systematic review and meta-analysis. JAMA 311:1889-900
9. Dole VP. 1988. Implications of methadone maintenance for theories of narcotic addiction. JAMA 260:3025-29
10. Haney M, Hart CL, Vosburg SK, Nasser J, Bennett A, et al. 2004. Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology 29:158-70
11. Evans DE, Drobes DJ. 2009. Nicotine self-medication of cognitive-attentional processing. Addict. Biol. 14:32-42
12. Kassel JD, Unrod M. 2000. Smoking, anxiety, and attention: support for the role of nicotine in attentionally mediated anxiolysis. J. Abnorm. Psychol. 109:161-66
13. Koob GF, Kreek MJ. 2007. Stress, dysregulation of drug reward pathways, and the transition to drug dependence. Am. J. Psychiatry 164:1149-59
14. Marlatt G, Gordon J. 1980. Determinants of relapse: implications for the maintenance of behavioral change. In BehavioralMedicine: Changing Health Lifestyles, ed. P Davidson, S Davidson, pp. 410-52. New York: Brunner/Mazel
15. Mason BJ, Light JM, Williams LD, Drobes DJ. 2009. Proof-of-concept human laboratory study for protracted abstinence in alcohol dependence: effects of gabapentin. Addict. Biol. 14:73-83
16. Mason BJ, Light JM, Escher T, Drobes DJ. 2008. Effect of positive and negative affective stimuli and beverage cues on measures of craving in non treatment-seeking alcoholics. Psychopharmacology 200:141-50
17. Sinha R. 2009. Modeling stress and drug craving in the laboratory: implications for addiction treatment development. Addict. Biol. 14:84-98
18. Lang P, Kozak MJ,Miller GA, Levin DN, McLean A Jr. 1980. Emotional imagery: conceptual structure and pattern of somatovisceral response. Psychophysiology 17:179-92
19. Fox HC, Talih M, Malison R, Anderson GM, Kreek MJ, Sinha R. 2005. Frequency of recent cocaine and alcohol use affects drug craving and associated responses to stress and drug-related cues. Psychoneuroendicrinology 30:880-91
20. al'Absi M, Hatsukami D, Davis GL. 2005. Attenuated adrenocorticotropic responses to psychological stress are associated with early smoking relapse. Psychopharmacology 181:107-17
21. Higley AE, CraneNA, Spadoni AD, Quello SB,Goodell V, Mason BJ. 2011. Craving in response to stress induction in a human laboratory paradigm predicts treatment outcome in alcohol-dependent individuals. Psychopharmacology 218:121-29
22. Vendruscolo LF, Estey D, Goodell V, Macshane LG, Logrip ML, et al. 2015. Glucocorticoid receptor antagonism decreases alcohol seeking in alcohol-dependent individuals. J. Clin. Investig. 125:3193-97
23. Mason BJ, Goodman AM, Chabac S, Lehert P. 2006. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: The role of patient motivation. J. Psychiatr. Res. 40:383-93
24. Mason BJ, Quello S, Goodell V, Shadan F, KyleM, Begovic A. 2014. Gabapentin treatment for alcohol dependence: A randomized clinical trial. JAMA Intern. Med. 174:70-77
25. Shaham Y, ShalevU, Lu L, deWit H, Stewart J. 2003. The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology 168:3-20
26. SchultzW. 2007. Multiple dopamine functions at different time courses. Annu. Rev. Neurosci. 30:259-88
27. Le Merrer J, Becker JA, Befort K, Kieffer BL. 2009. Reward processing by the opioid system in the brain. Physiol. Rev. 89:1379-412
28. Tolu S, Eddine R, Marti F, David V, Graupner M, et al. 2013. Co-activation of VTA DA and GABA neurons mediates nicotine reinforcement. Mol. Psychiatry 18:382-93
29. Weiss F, Markou A, Lorang MT, Koob GF. 1992. Basal extracellular dopamine levels in the nucleus accumbens are decreased during cocaine withdrawal after unlimited-access self-administration. Brain Res. 593:314-18
30. Diana M, Pistis M, Carboni S, Gessa GL, Rossetti ZL. 1993. Profound decrement of mesolimbic dopaminergic neuronal activity during ethanol withdrawal syndrome in rats: electrophysiological and biochemical evidence. PNAS 90:7966-69
31. DianaM, PistisM,Muntoni A, Gessa G. 1995. Profound decrease ofmesolimbic dopaminergic neuronal activity in morphine withdrawn rats. J. Pharmacol. Exp. Ther. 272:781-85
32. Nestler EJ. 1996. Under siege: The brain on opiates. Neuron 16:897-900
33. Weiss F, Parsons LH, Schulteis G, Hyytia P, Lorang MT, et al. 1996. Ethanol self-administration restores withdrawal-associated deficiencies in accumbal dopamine and 5-hydroxytryptamine release in dependent rats. J. Neurosci. 16:3474-85
34. Melis M, Spiga S, DianaM. 2005. The dopamine hypothesis of drug addiction: hypodopaminergic state. Int. Rev. Neurobiol. 63:101-54
35. Collier HO. 1980. Cellular site of opiate dependence. Nature 283:625-29
36. Koob GF, Volkow ND. 2010. Neurocircuitry of addiction. Neuropsychopharmacol. Rev. 35:217-38.
37. Erratum. 2010. Neuropsychopharmacol. Rev. 35:1051
38. Mello NK, Mendelson JH. 1980. Buprenorphine suppresses heroin use by heroin addicts. Science 207:657-59
39. Tzschentke TM. 2002. Behavioral pharmacology of buprenorphine, with a focus on preclinical models of reward and addiction. Psychopharmacology 161:1-16
40. Cowan A. 2007. Buprenorphine: The basic pharmacology revisited. J. Addict. Med. 1:68-72
41. Wade CL, Vendruscolo LF, Schlosburg JE, Hernandez DO, Koob GF. 2015. Compulsive-like responding for opioid analgesics in rats with extended access. Neuropsychopharmacology 40:421-28
42. Negus SS, Woods JH. 1995. Reinforcing effects, discriminative stimulus effects and physical dependence liability of buprenorphine. In Buprenorphine: Combatting Drug Abuse with a Unique Opioid, ed. A Cowan, JW Lewis, pp. 71-101. New York: Wiley-Liss
43. Mello NK, Lukas SE, Bree MP, Mendelson JH. 1988. Progressive ratio performance maintained by buprenorphine, heroin and methadone in Macaque monkeys. Drug Alcohol Depend. 21:81-97
44. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE. 1976. The effects of morphine-and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 197:517-32
45. Jasinski DR, Pevnick JS, Griffith JD. 1978. Human pharmacology and abuse potential of the analgesic buprenorphine: A potential agent for treating narcotic addiction. Arch. Gen. Psychiatry 35:501-16
46. Mello NK, Bree MP, Mendelson JH. 1983. Comparison of buprenorphine and methadone effects on opiate self-administration in primates. J. Pharmacol. Exp. Ther. 225:378-86
47. Winger G, Skjoldager P, Woods JH. 1992. Effects of buprenorphine and other opioid agonists and antagonists on alfentanil-and cocaine-reinforced responding in rhesus monkeys. J. Pharmacol. Exp. Ther. 261:311-17
48. Comer SD, Collins ED, Fischman MW. 2001. Buprenorphine sublingual tablets: effects on IV heroin self-administration by humans. Psychopharmacology 154:28-37
49. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, et al. 2006. Efficacy of varenicline, an4-2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: A randomized controlled trial. JAMA 296:56-63.
50. Erratum. 2006. JAMA 296:1355
51. Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, et al. 2007. Pharmacological profile of the4-2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 52:985-94
52. Biala G, Staniak N, Budzynska B. 2010. Effects of varenicline and mecamylamine on the acquisition, expression, and reinstatement of nicotine-conditioned place preference by drug priming in rats. Naunyn Schmiedeberg's Arch. Pharmacol. 381:361-70
53. Spiller K, Xi ZX, Li X, Ashby CR Jr, Callahan PM, et al. 2009. Varenicline attenuates nicotine-enhanced brain-stimulation reward by activation of4-2 nicotinic receptors in rats. Neuropharmacology 57:60-66
54. Smith JW, Mogg A, Tafi E, Peacey E, Pullar IA, et al. 2007. Ligands selective for4-2 but not3-4 or7 nicotinic receptors generalise to the nicotine discriminative stimulus in the rat. Psychopharmacology 190:157-70
55. Igari M, Alexander JC, Ji Y, Qi X, Papke RL, Bruijnzeel AW. 2014. Varenicline and cytisine diminish the dysphoric-like state associated with spontaneous nicotine withdrawal in rats. Neuropsychopharmacology 39:455-65
56. Foulds J, Russ C, Yu CR, Zou KH, Galaznik A, et al. 2013. Effect of varenicline on individual nicotine withdrawal symptoms: A combined analysis of eight randomized, placebo-controlled trials. Nicotine Tob. Res. 15:1849-57
57. George O, Ghozland S, Azar MR, Cottone P, Zorrilla EP, et al. 2007. CRF-CRF1 system activation mediates withdrawal-induced increases in nicotine self-administration in nicotine-dependent rats. PNAS 104:17198-203
58. George O, Lloyd A, Carroll FI, Damaj MI, Koob GF. 2011. Varenicline blocks nicotine intake in rats with extended access to nicotine self-administration. Psychopharmacology 213:715-22
59. Pulvirenti L, Koob GF. 2002. Being partial to psychostimulant addiction therapy. Trends Pharmacol. Sci. 23:151-53
60. Wee S, Wang Z, Woolverton WL, Pulvirenti L, Koob GF. 2007. Effect of aripiprazole, a partial D2 receptor agonist, on increased rate of methamphetamine self-administration in rats with prolonged access. Neuropsychopharmacology 32:2238-47
61. Vergne DE, Anton RF. 2010. Aripiprazole: A drug with a novel mechanism of action and possible efficacy for alcohol dependence. CNS Neurol. Disord. Drug Targets 9:50-54
62. de Witte P, Littleton J, Parot P, Koob G. 2005. Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action. CNS Drugs 19:517-37
63. Littleton JM. 2007. Acamprosate in alcohol dependence: implications of a unique mechanism of action. J. Addict. Med. 1:115-25
64. Spanagel R, Kiefer F. 2008. Drugs for relapse prevention of alcoholism: ten years of progress. Trends Pharmacol. Sci. 29:109-15
65. Kalivas PW, McFarland K, Bowers S, Szumlinski K, Xi ZX, Baker D. 2003. Glutamate transmission and addiction to cocaine. In Glutamate and Disorders of Cognition and Motivation, ed. BMoghaddam, ME Wolf, pp. 169-75. New York: N. Y. Acad. Sci.
66. Everitt BJ, Wolf ME. 2002. Psychomotor stimulant addiction: A neural systems perspective. J. Neurosci. 22:3312-20.
67. Erratum. 2002. J. Neurosci. 22(16):1a
68. Vorel SR, Liu X,Hayes RJ, Spector JA, Gardner EL. 2001. Relapse to cocaine-seeking after hippocampal theta burst stimulation. Science 292:1175-78
69. Backstrom P, Hyytia P. 2006. Ionotropic and metabotropic glutamate receptor antagonism attenuates cue-induced cocaine seeking. Neuropsychopharmacology 31:778-86
70. Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. 2000. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 41(Suppl. 1):S3-9
71. Stringer S, Rueve M, Mossman D. 2008. Topiramate as treatment for alcohol dependence. J. Am. Med. Assoc. 299:405-6
72. Olmsted CL, Kockler DR. 2008. Topiramate for alcohol dependence. Ann. Pharmacother. 42:1475-80
73. Farook JM, Lewis B, Littleton JM, Barron S. 2009. Topiramate attenuates the stress-induced increase in alcohol consumption and preference in male C57BL/6J mice. Physiol. Behav. 96:189-93
74. Koob GF. 2008. A role for brain stress systems in addiction. Neuron 59:11-34
75. Koob GF. 2013. Addiction is a reward deficit and stress surfeit disorder. Front. Psychiatry 4:72
76. Vendruscolo LF, Barbier E, Schlosburg JE, Misra KK, Whitfield T Jr, et al. 2012. Corticosteroiddependent plasticity mediates compulsive alcohol drinking in rats. J. Neurosci. 32:7563-71
77. Bruijnzeel AW, Zislis G, Wilson C, Gold MS. 2007. Antagonism of CRF receptors prevents the deficit in brain reward function associated with precipitated nicotine withdrawal in rats. Neuropsychopharmacology 32:955-63
78. Bruijnzeel AW, Small E, Pasek TM, Yamada H. 2010. Corticotropin-releasing factor mediates the dysphoria-like state associated with alcohol withdrawal in rats. Behav. Brain Res. 210:288-91
79. Specio SE, Wee S, O'Dell LE, Boutrel B, Zorrilla EP, Koob GF. 2008. CRF1 receptor antagonists attenuate escalated cocaine self-administration in rats. Psychopharmacology 196:473-82
80. Greenwell TN, Funk CK, Cottone P, Richardson HN, Chen SA, et al. 2009. Corticotropin-releasing factor-1 receptor antagonists decrease heroin self-administration in long-but not short-access rats. Addict. Biol. 14:130-43
81. Funk CK, Zorrilla EP, Lee MJ, Rice KC, Koob GF. 2007. Corticotropin-releasing factor 1 antagonists selectively reduce ethanol self-administration in ethanol-dependent rats. Biol. Psychiatry 61:78-86
82. Sommer WH, Rimondini R, Hansson AC, Hipskind PA, Gehlert DR, et al. 2008. Upregulation of voluntary alcohol intake, behavioral sensitivity to stress, and amygdala Crhr1 expression following a history of dependence. Biol. Psychiatry 63:139-45
83. Valdez GR, Roberts AJ, Chan K, DavisH, BrennanM, et al. 2002. Increased ethanol self-administration and anxiety-like behavior during acute withdrawal and protracted abstinence: regulation by corticotropinreleasing factor. Alcohol. Clin. Exp. Res. 26:1494-501
84. Gehlert DR, Cippitelli A, Thorsell A, Le AD, Hipskind PA, et al. 2007. 3-(4-Chloro-2-morpholin-4-ylthiazol-5-yl)-8-(1-ethylpropyl)-2,6-dimethyl-imidazo[1,2-b]pyridazine: A novel brain-penetrant, orally available corticotropin-releasing factor receptor 1 antagonistwith efficacy in animal models of alcoholism. J. Neurosci. 27:2718-26
85. Funk CK, O'Dell LE, Crawford EF, Koob GF. 2006. Corticotropin-releasing factor within the central nucleus of the amygdala mediates enhanced ethanol self-administration in withdrawn, ethanol-dependent rats. J. Neurosci. 26:11324-32
86. Nestler EJ. 2004. Historical review: molecular and cellular mechanisms of opiate and cocaine addiction. Trends Pharmacol. Sci. 25:210-18
87. Shippenberg TS, Zapata A, Chefer VI. 2007. Dynorphin and the pathophysiology of drug addiction. Pharmacol. Ther. 116:306-21
88. Wee S, Koob GF. 2010. The role of the dynorphin-opioid system in the reinforcing effects of drugs of abuse. Psychopharmacology 210:121-35
89. Wee S, Orio L, Ghirmai S, Cashman JR, Koob GF. 2009. Inhibition of opioid receptors attenuated increased cocaine intake in rats with extended access to cocaine. Psychopharmacology 205:565-75
90. Walker BM, Zorrilla EP, Koob GF. 2010. Systemic opioid receptor antagonism by norbinaltorphimine reduces dependence-induced excessive alcohol self-administration in rats. Addict. Biol. 16:116-19
91. Schlosburg JE, WhitfieldTWJr, Park PE, Crawford EF, George O, et al. 2013. Long-term antagonism of opioid receptors prevents escalation of and increased motivation for heroin intake. J. Neurosci. 33:19384-92
92. Whitfield TW Jr, Schlosburg J,Wee S, Vendruscolo L, Gould A, et al. 2015. opioid receptors in the nucleus accumbens shell mediate escalation of methamphetamine intake. J. Neurosci. 35(10):4296-305
93. Nealey KA, Smith AW, Davis SM, Smith DG, Walker BM. 2011. Opioid receptors are implicated in the increased potency of intra-accumbens nalmefene in ethanol-dependent rats. Neuropharmacology 61:35-42
94. Barbier E, Vendruscolo LF, Schlosburg JE, Edwards S, Juergens N, et al. 2013. The NK1 receptor antagonist L822429 reduces heroin reinforcement. Neuropsychopharmacology 38:976-84
95. Schmeichel BE, Barbier E, Misra KK, Contet C, Schlosburg JE, et al. 2015. Hypocretin receptor 2 antagonism dose-dependently reduces escalated heroin self-administration in rats. Neuropsychopharmacology 40:1123-29
96. Heilig M, Koob GF. 2007. A key role for corticotropin-releasing factor in alcohol dependence. Trends Neurosci. 30:399-406
97. Valdez GR,Koob GF. 2004. Allostasis and dysregulation of corticotropin-releasing factor and neuropeptide Y systems: implications for the development of alcoholism. Pharmacol. Biochem. Behav. 79:671-89
98. Meunier JC, Mollereau C, Toll L, Suaudeau C, Moisand C, et al. 1995. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 377:532-35
99. Reinscheid RK, Nothacker HP, Bourson A, Ardati A, Henningsen RA, et al. 1995. Orphanin FQ: A neuropeptide that activates an opioidlike G protein-coupled receptor. Science 270:792-94
100. Ciccocioppo R, Economidou D, Fedeli A, Massi M. 2003. The nociceptin/orphanin FQ/NOP receptor system as a target for treatment of alcohol abuse: A review of recent work in alcohol-preferring rats. Physiol. Behav. 79:121-28
101. Martin-Fardon R, Zorrilla EP, Ciccocioppo R, Weiss F. 2010. Role of innate and drug-induced dysregulation of brain stress and arousal systems in addiction: focus on corticotropin-releasing factor, nociceptin/orphanin FQ, and orexin/hypocretin. Brain Res. 1314:145-61
102. Patel S, Roelke CT, Rademacher DJ, Hillard CJ. 2005. Inhibition of restraint stress-induced neural and behavioural activation by endogenous cannabinoid signalling. Eur. J. Neurosci. 21:1057-69
103. Serrano A, Parsons LH. 2011. Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors. Pharmacol. Ther. 132:215-41
104. Bajo M, Cruz MT, Siggins GR, Messing R, Roberto M. 2008. Protein kinase C mediation of CRFand ethanol-induced GABA release in central amygdala. PNAS 105:8410-15
105. Roberto M, Gilpin NW, O'Dell LE, Cruz MT, Morse AC, et al. 2008. Cellular and behavioral interactions of gabapentin with alcohol dependence. J. Neurosci. 28:5762-71
106. RobertoM, CruzMT, Gilpin NW, Sabino V, Schweitzer P, et al. 2010. Corticotropin releasing factorinduced amygdala gamma-aminobutyric acid release plays a key role in alcohol dependence. Biol. Psychiatry 67:831-39
107. Kallupi M, Wee S, Edwards S, Whitfield TW Jr, Oleata CS, et al. 2013. opioid receptor-mediated dysregulation of GABAergic transmission in the central amygdala in cocaine addiction. Biol. Psychiatry 74:520-28
108. RobertoM, Gilpin NW. 2014. Central amygdala neuroplasticity in alcohol dependence. In Neurobiology of Alcohol Dependence, ed. A Noronha, C Cui, A Harris, J Crabbe, pp. 207-20. New York: Elsevier
109. Chung K, Deisseroth K. 2013. CLARITY for mapping the nervous system. Nat. Methods 10:508-13.
110. Erratum. 2013. Nat. Methods 10:1035
111. Nussinov R, Tsai CJ. 2015. The design of covalent allosteric drugs. Annu. Rev. Pharmacol. Toxicol. 55:249-67
112. Day JJ, Kennedy AJ, Sweatt JD. 2015. DNA methylation and its implications and accessibility for neuropsychiatric therapeutics. Annu. Rev. Pharmacol. Toxicol. 55:591-611
113. Moonat S, Sakharkar AJ, ZhangH, Pandey SC. 2011. The role of amygdaloid brain-derived neurotrophic factor, activity-regulated cytoskeleton-associated protein and dendritic spines in anxiety and alcoholism. Addict. Biol. 16:238-50
114. Treutlein J, Kissling C, Frank J, Wiemann S, Dong L, et al. 2006. Genetic association of the human corticotropin releasing hormone receptor 1 (CRHR1) with binge drinking and alcohol intake patterns in two independent samples. Mol. Psychiatry 11:594-602
115. Blomeyer D, Treutlein J, Esser G, Schmidt MH, Schumann G, Laucht M. 2008. Interaction between CRHR1 gene and stressful life events predicts adolescent heavy alcohol use. Biol. Psychiatry 63:146-51
116. Schmid B, Blomeyer D, Treutlein J, Zimmermann US, Buchmann AF, et al. 2010. Interacting effects of CRHR1 gene and stressful life events on drinking initiation and progression among 19-year-olds. Int. J. Neuropsychopharmacol. 13:703-14
117. Chen AC, Manz N, Tang Y, Rangaswamy M, Almasy L, et al. 2010. Single-nucleotide polymorphisms in corticotropin releasing hormone receptor 1 gene (CRHR1) are associated with quantitative trait of event-related potential and alcohol dependence. Alcohol. Clin. Exp. Res. 34:988-96
118. Sommer WH, Lidström J, Sun H, Passer D, Eskay R, et al. 2010. Human NPY promoter variation rs16147:T>C as a moderator of prefrontal NPY gene expression and negative affect. Hum. Mutat. 31:E1594-608
119. Zhou Z, ZhuG,Hariri AR, EnochMA, ScottD, et al. 2008. Genetic variation in human NPY expression affects stress response and emotion. Nature 452:997-1001
120. Donner J, Sipilä T, Ripatti S, Kananen L, Chen X, et al. 2012. Support for involvement of glutamate decarboxylase 1 and neuropeptide Y in anxiety susceptibility. Am. J. Med. Genet. B Neuropsychiatr. Genet. 159B:316-27
121. Wetherill L, Schuckit MA, Hesselbrock V, Xuei X, Liang T, et al. 2008. Neuropeptide Y receptor genes are associated with alcohol dependence, alcohol withdrawal phenotypes, and cocaine dependence. Alcohol. Clin. Exp. Res. 32:2031-40
122. Bhaskar LV, Thangaraj K, Kumar KP, Pardhasaradhi G, Singh L, Rao VR. 2013. Association between neuropeptide Y gene polymorphisms and alcohol dependence: A case-control study in two independent populations. Eur. Addict. Res. 19:307-13
123. Mutschler J, Abbruzzese E, von der Goltz C, Dinter C, Mobascher A, et al. 2012. Genetic variation in the neuropeptide Y gene promoter is associated with increased risk of tobacco smoking. Eur. Addict. Res. 18:246-52
124. Okahisa Y, Ujike H, Kotaka T, Morita Y, Kodama M, et al. 2009. Association between neuropeptide Y gene and its receptor Y1 gene and methamphetamine dependence. Psychiatry Clin. Neurosci. 63:417-22
125. Collins FS, Varmus H. 2015. A new initiative on precision medicine. N. Engl. J. Med. 372:793-95
126. Insel PA, Amara SG, Blaschke TF. 2015. Introduction to the theme "PrecisionMedicine and Prediction in Pharmacology. " Annu. Rev. Pharmacol. Toxicol. 55:11-14
127. Dunnenberger HM, Crews KR, Hoffman JM, Caudle KE, Broeckel U, et al. 2015. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annu. Rev. Pharmacol. Toxicol. 55:89-106
128. Gross ER, Zambelli VO, Small BA, Ferreira JC, Chen CH, Mochly-Rosen D. 2015. A personalized medicine approach for Asian Americans with the aldehyde dehydrogenase 2-2 variant. Annu. Rev. Pharmacol. Toxicol. 55:107-27
129. ChuK,Koob GF,ColeM, Zorrilla EP, Roberts AJ. 2007. Dependence-induced increases in ethanol selfadministration in mice are blocked by the CRF1 receptor antagonist antalarmin and by CRF1 receptor knockout. Pharmacol. Biochem. Behav. 86:813-21
130. Gilpin NW,Misra K, Koob GF. 2008. Neuropeptide Y in the central nucleus of the amygdala suppresses dependence-induced increases in alcohol drinking. Pharmacol. Biochem. Behav. 90:475-80
131. Overstreet DH, Knapp DJ, Breese GR. 2007. Drug challenges reveal differences in mediation of stress facilitation of voluntary alcohol drinking and withdrawal-induced anxiety in alcohol-preferring P rats. Alcohol. Clin. Exp. Res. 31:1473-81
132. Sabino V, Cottone P, Koob GF, Steardo L, LeeMJ, et al. 2006. Dissociation between opioid and CRF1 antagonist sensitive drinking in Sardinian alcohol-preferring rats. Psychopharmacology 189:175-86
133. Richardson HN, Zhao Y, Fekete EM, Funk CK, Wirsching P, et al. 2008. MPZP: A novel small molecule corticotropin-releasing factor type 1 receptor (CRF1) antagonist. Pharmacol. Biochem. Behav. 88:497-510
134. Walker BM, Rasmussen DD, Raskind MA, Koob GF. 2008. 1-Noradrenergic receptor antagonism blocks dependence-induced increases in responding for ethanol. Alcohol 42:91-97
135. Skelly MJ,Weiner JL. 2014. Chronic treatment with prazosin or duloxetine lessens concurrent anxietylike behavior and alcohol intake: evidence of disrupted noradrenergic signaling in anxiety-related alcohol use. Brain Behav. 4:468-83
136. Gilpin NW, Koob GF. 2010. Effects of adrenoceptor antagonists on alcohol drinking by alcoholdependent rats. Psychopharmacology 212:431-39
137. Walker BM, Koob GF. 2008. Pharmacological evidence for a motivational role of opioid systems in ethanol dependence. Neuropsychopharmacology 33:643-52
138. Walker BM, Koob GF. 2007. The aminobutyric acid-B receptor agonist baclofen attenuates responding for ethanol in ethanol-dependent rats. Alcohol. Clin. Exp. Res. 31:11-18
139. Gilpin NW. 2012. Neuropeptide Y (NPY) in the extended amygdala is recruited during the transition to alcohol dependence. Neuropeptides 46:253-59
140. RimondiniR,ThorsellA,HeiligM. 2005. Suppression of ethanol self-administration by the neuropeptide Y (NPY) Y2 receptor antagonist BIIE0246: evidence for sensitization in ratswith a history of dependence. Neurosci. Lett. 375:129-33
141. GilpinNW,Richardson HN, Koob GF. 2008. Effects of CRF1-receptor and opioid-receptor antagonists on dependence-induced increases in alcohol drinking by alcohol-preferring (P) rats. Alcohol. Clin. Exp. Res. 32:1535-42
142. Abulseoud OA, Camsari UM, Ruby CL, Kasasbeh A, Choi S, Choi DS. 2014. Attenuation of ethanol withdrawal by ceftriaxone-induced upregulation of glutamate transporter EAAT2. Neuropsychopharmacology 39:1674-84
143. Hinton DJ, LeeMR, Jacobson TL,Mishra PK, Frye MA, et al. 2012. Ethanol withdrawal-induced brain metabolites and the pharmacological effects of acamprosate in mice lacking ENT1. Neuropharmacology 62:2480-88
144. GriffinWCIII, Haun HL, Hazelbaker CL, Ramachandra VS, Becker HC. 2014. Increased extracellular glutamate in the nucleus accumbens promotes excessive ethanol drinking in ethanol dependent mice. Neuropsychopharmacology 39:707-17
145. Alaux-Cantin S, Buttolo R, Houchi H, Jeanblanc J, Naassila M. 2015. Memantine reduces alcohol drinking but not relapse in alcohol-dependent rats. Addict. Biol. 20:890-901
146. Smith AW, Nealey KA, Wright JW, Walker BM. 2011. Plasticity associated with escalated operant ethanol self-administration during acute withdrawal in ethanol-dependent rats requires intact matrix metalloproteinase systems. Neurobiol. Learn. Mem. 96:199-206
147. Qiang M, Li JG, Denny AD, Yao JM, Lieu M, et al. 2014. Epigenetic mechanisms are involved in the regulation of ethanol consumption in mice. Int. J. Neuropsychopharmacol. 18(2):1-11
148. Koob GF. 2015. The dark side of emotion: The addiction perspective. Eur. J. Pharmacol. 753:73-87